Affymetrix and Vita Genomics Collaborate to Develop Microarray-based IVD Products
Affymetrix Inc. and Vita Genomics announced that Affymetrix has granted Vita Genomics and its fully owned subsidiary, Shanghai GeneCore BioTechnologies, non-exclusive access to Affymetrix microarray technology to develop and market in-vitro diagnostic (IVD) tests for Alpha interferon Treatment response in patients with HBV and HCV, as well as for early onset and allergic asthma in infants and young children. The resulting microarray-based IVD products would provide clinicians with better diagnosis methods and more efficient approaches for treating patients and managing these diseases.
As part of the Powered by Affymetrix(TM) program, Vita Genomics is able to incorporate Affymetrix' patented arrays into its molecular diagnostic assays developed to predict drug efficacy prior to treatment and assess risks to facilitate disease prevention.
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Windkessel_effect
Hypotonic

Predicting the Long-Term Stability of Biologics - Analysis of Formulation-Dependent Colloidal and Conformational Stability of Monoclonal Antibodies
Scientists find a brake that acts when cellular motors run too far - Cell-organisation better understood

BIOTECH AUSTRIA calls for better framework conditions for the biotechnology sector of the future - Proposals provide impetus for research, infrastructure and investments in Austria

LUMiSizer | Nanoparticle analyzers | LUM
Antitope and Synthon announce collaboration
Analysis by AlgoNomics reveals that Anticalins have an immunogenicity level comparable to the wild-type human lipocalin
Cellectis Acquires Vectocell Technology to Accelerate Therapeutic Development Programs
New data for Menveo vaccine show excellent immune response and broad protection for infants against meningococcal meningitis - Menveo (MenACWY-CRM) the first quadrivalent conjugated meningitis vaccine to demonstrate an excellent immune response in infants
Kentucky Bioprocessing, Icon Genetics and Mapp Biopharmaceutical have entered into discussions to merge their businesses
